

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: B. F. Johnson et al.

: Group Art Unit: 1646

Serial No.: 10/691,533

: Examiner:

Filed: October 24, 2003

:

For LABELED LIGANDS FOR LECTIN-LIKE
OXIDIZED LOW-DENSITY LIPOPROTEIN
RECEPTOR (LOX-1)

:

SUPPLEMENTAL INFORMATION
DISCLOSURE STATEMENT

- ☐ 1 **Pursuant to 37 CFR 1.97(b)**
[within 3 months of national, non-CPA filing or prior to 1st Office Action] *no charge*
- ☒ 2 **Certification Pursuant to 37 CFR 1.97(c)(1)**
[before Final Office Action, Allowance, or other action closing prosecution] *no charge*
- ☐ 3 **Fee Payment Pursuant to 37 CFR 1.97(c)(2)**
[before Final Office Action, Allowance, or other action closing prosecution] *\$180.00*
- ☐ 4 **Certification & Fee Payment Pursuant to 37 CFR 1.97(d)**
[On or before issue fee payment] *\$180.00*

ATTN: MAILSTOP PATENT APPLICATION
COMMISSIONER FOR PATENTS
ALEXANDRIA, VA 22313-1450

Sir:

The following are submitted in the above identified application in compliance with 37 CFR 1.97 & 37 CFR 1.98:

- ☒ 5 A list of documents on form PTO-1449 or Substitute together with copies of each identified document and a translation thereof or a concise explanation of each non-English language document or a Search Report from an International Searching Authority for a patent application filed via the Patent Cooperation Treaty or document(s) cited in the application or the priority application.

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Assistant Commissioner for Patents, Washington, D.C. 20231, on the date indicated below.

Date of Deposit_____
Type or Print Name_____
Signature

This paper is submitted in accordance with:

- ☐ 6 37 CFR 1.97(b): [within 3 months of national, non-CPA filing or prior to 1st Office Action]
- ☒ 7 37 CFR 1.97(c): [before Final Office Action, Allowance, or other action closing prosecution, whichever is earlier]; and
- ☒ 8 The required Certification made in item 11 below; or
- ☐ 9 The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 15 below.
- ☐ 10 37 CFR §1.97(d): [On or before issue fee payment]; and
- a) The required Certification is stated in item 11 below; and
- b) The \$180.00 fee specified in 37 CFR 1.17(p) for submission of this Information Disclosure Statement is authorized in item 14 below.
- ☒ 11 Certification
- ☐ 12 Each item of information contained in this Statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Statement; or
- ☒ 13 No item of information contained in this Statement was cited in a communication from a foreign patent office in a counterpart foreign application and, to the knowledge of the person signing this document after making reasonable inquiry, no item of information contained in this Statement was known to any individual designated in 37 CFR 1.56(c) more than three (3) months prior to the filing of this Statement.
- ☒ 14 Payment of all applicable fees:
- ☒ 15 Please charge all applicable fees associated with the submittal of this Information Disclosure Statement and any other fees applicable to this application to Deposit Account No. 07-0868. An original and two (2) copies of this document are enclosed.

September 22, 2004

Date

General Electric Company
GEGR Patent Docket Rm. Bldg. K-1 Rm. 4A59
One Research Circle
Niskayuna, New York 12309
Customer Number: 006147

Respectfully submitted,

Toan P. Vo

Attorney - Toan P. Vo
Registration No. 43,225
Phone: (518) 387-6648
or (518) 387-7122

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

130633

SERIAL NO.

10/691,533

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--

SEP 29 2004

LIST OF ITEMS

Applicant

B. F. Johnson et al.

Filing Date

October 24, 2003

Group

1646

(Use several sheets if necessary)

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA 6 7 1 3 0 4 2	03/30/04	Liu			
	AB 6 5 1 7 8 1 4	02/11/03	Liu			
	AC					
	AD					
	AE					
	AF					
	AG					
	AH					
	AI					
	AJ					
	AK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	No
	AL 9 6 4 0 4 3 7	12/19/96	International Application				
	AM						
	AN						
	AO						
	AP						

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc.)

AR	US Patent Application Publication 20030103995, Issued 1/5/03, Hamblin et al.
AS	US Patent Application Publication 20040067200, Issued 4/8/04, Liu
AT	G. U. Gurudutta et al., "Evaluation of potential tracer ability of 99mTc-labeled acetylated LDL for scintigraphy of LDL-scavenger receptor sites of macrophageal origin", Nuclear Medicine and Piology, 28 (2001) 235-241.

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM PTO-1449
(REV. 7-80)
(Title Amended 3/83)

U.S. DEPARTMENT OF COMMERCE
PATENT AND TRADEMARK OFFICE

ATTY. DOCKET NO.

130633

SERIAL NO.

10/691,533

INFORMATION DISCLOSURE STATEMENT BY APPLICANT--

LIST OF ITEMS

(Use several sheets if necessary)

Applicant

B. F. Johnson et al.

Filing Date

October 24, 2003

Group

1646

U.S. PATENT DOCUMENTS

*EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	BA					
	BB					
	BC					
	BD					
	BE					
	BF					
	BG					
	BH					
	BI					
	BJ					
	BK					

FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	No
	BL						
	BM						
	BN						
	BO						
	BP						

OTHER INFORMATION (Including Author, Title, Date, Pertinent pages. Etc.)

BR	Juliano et al., "Preparation of biodistribution of 99mtechnetium labelled oxidized LDL in man", Atherosclerosis, 126 (1996) 131-141
BS	S. Tsimikas, MD., "Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with lagged oxidation-specific antibodies", Am J. Cardiol. 90(10C), 22L-26L.
BT	

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.